Envista Holdings Corporation (NYSE:NVST) Receives Average Recommendation of “Hold” from Analysts

Shares of Envista Holdings Corporation (NYSE:NVST) have earned a consensus recommendation of “Hold” from the sixteen brokerages that are currently covering the company, Marketbeat Ratings reports. Ten investment analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $28.6154.

Several analysts recently commented on the company. Piper Sandler raised their target price on Envista from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday. Morgan Stanley boosted their price target on Envista from $19.00 to $21.00 and gave the stock an “equal weight” rating in a research report on Friday, April 24th. Robert W. Baird increased their price target on Envista from $30.00 to $31.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. Wall Street Zen lowered Envista from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Finally, Barclays cut their price objective on shares of Envista from $34.00 to $32.00 and set an “overweight” rating on the stock in a research note on Thursday, June 11th.

Institutional Trading of Envista

A number of hedge funds and other institutional investors have recently made changes to their positions in NVST. Tudor Investment Corp ET AL acquired a new position in shares of Envista during the third quarter valued at approximately $1,664,000. Massachusetts Financial Services Co. MA raised its holdings in Envista by 15.3% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 3,349,874 shares of the company’s stock worth $72,726,000 after purchasing an additional 444,725 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Envista by 1.6% in the first quarter. Dimensional Fund Advisors LP now owns 9,780,948 shares of the company’s stock worth $248,130,000 after purchasing an additional 152,488 shares during the period. Royce & Associates LP lifted its position in Envista by 11.6% in the fourth quarter. Royce & Associates LP now owns 996,147 shares of the company’s stock worth $21,626,000 after purchasing an additional 103,312 shares during the period. Finally, Jackson Creek Investment Advisors LLC bought a new position in Envista during the 4th quarter valued at $1,447,000.

Envista Trading Down 1.4%

Shares of NYSE:NVST opened at $27.39 on Tuesday. The company has a quick ratio of 2.06, a current ratio of 2.44 and a debt-to-equity ratio of 0.47. The company’s 50-day moving average price is $25.59 and its 200 day moving average price is $25.89. The company has a market cap of $4.46 billion, a PE ratio of 66.80, a P/E/G ratio of 1.55 and a beta of 0.86. Envista has a fifty-two week low of $18.77 and a fifty-two week high of $30.42.

Envista (NYSE:NVST) last posted its earnings results on Wednesday, May 6th. The company reported $0.36 EPS for the quarter, topping the consensus estimate of $0.31 by $0.05. Envista had a net margin of 2.41% and a return on equity of 7.11%. The firm had revenue of $705.50 million during the quarter, compared to analysts’ expectations of $680.03 million. During the same quarter in the prior year, the firm earned $0.24 EPS. Envista’s quarterly revenue was up 14.4% on a year-over-year basis. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. Sell-side analysts anticipate that Envista will post 1.42 earnings per share for the current year.

About Envista

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.